FDA
-
-
-
-
-
-
-
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
-
-
-
-
-
-
-
Adicet Bio reports initial lupus nephritis trial results
-
-
-
-
-
-
-
Adicet Bio (ACET) Appoints Michael Grissinger to the Board of Directors
-
-
-
-
-
-
-
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
-
-
-
-
-
-
-
Adicet Bio (ACET) Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Adicet Bio Inc. (ACET)
-
334,135 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


